GLP-1 use is altering grocery habits, dining menus, and product design in 2026 and beyond.
The oral Wegovy pill is now available for weight management. Learn how it works, who it helps most, how it compares with injectables, and how to discuss options with your clinician.
Early trials of gene-silencing drugs plus GLP-1s show promising fat loss, but big questions remain. Here is what the science suggests so far.
High cost and poor coverage make people stop GLP-1s early, reducing benefits and adherence.
Learn how to preserve and build muscle while losing weight on GLP-1s, including strength training, protein intake, and realistic expectations.
See how states, Medicare, Medicaid, and employer plans are handling GLP-1 coverage changes in 2026 and what it means for your insurance.
No. Telehealth providers vary in which GLP-1 medications they offer based on FDA rules, state laws, and clinical protocols.
Certain foods can worsen nausea, bloating, and reflux on GLP-1 medications. Learn which foods often trigger symptoms and which tend to help.
What’s actually changing for GLP-1 medications in 2026, what isn’t, and how new evidence is shaping care and expectations.
Peer-reviewed research shows GLP-1 medications do not meaningfully increase cancer risk. Here’s what large human studies say in 2026.
Learn common GLP-1 terms like semaglutide, tirzepatide, FDA-approved, off-label, and compounded in plain English with trusted sources.
Retatrutide shows major Phase 3 weight-loss results but remains investigational. Learn what’s real in 2026 and why social ads can be misleading.
